Building on decades of Academy activities related to substance use, this report emphasizes three guiding principles:
methadone treatment slots available at any given time: 26,000 methadone maintenance slots licensed and funded by OASAS and 9,000 methadone maintenance slots licensed, but not funded, by OASAS. There are 96 methadone treatment facilities--88 not-forprofit clinics and 8 for-profit clinics. One not-for-profit clinic specializes in treating pregnant users; another specializes in treating adolescents. Only five new methadone clinics have been licensed in New York State during the past 20 years. There are an additional 5,000 residential treatment slots, 94% of which adopt a drug-free, abstinence approach. OASAS recently reported that New York State drug treatment programs operated at near capacity during the period June 1992 through June 1995, with a 97% average utilization rate systemwide during the 3-year period, and a 99% average utilization rate during the 1995 budget year.
OASAS further estimates that there are 600,000 regular, noninjecting users of illegal drugs, including opiate drugs, in New York State needing some type of treatment. The majority of these people use cocaine or crack cocaine alone or in addition to heroin.
The New York State Department of Correctional Services estimates that approximately 74% of New York State's incarcerated population (over 68,000 inmates) is in need of addiction services, yet treatment in correctional facilities is limited to about 9,800 drugfree, abstinence slots at any given time. (Methadone maintenance treatment is not available in New York State correctional facilities.)
To reduce the harms related to injection drug use, the New York State Department of Health, under special state regulations, supports 26 approved sites for needle and syringe exchange through 11 AIDS Institute programs. These programs serve an estimated 30,000 to 40,000 injection drug users, representing 14% of the state's injecting drug user population. Because of federal funding restrictions, these programs cannot use federal grants to support needle exchange activities. In addition, New York State is one of nine states and the District of Columbia that bar the sale of hypodermic needles and syringes without a prescription.
Recommendations

1.
We support significantly increased funding for addiction treatment, including methadone treatment, residential drug-free programs, and other modalities. 2. The level and duration of drug treatment should be a medical determination. We oppose legislative or regulatory proposals to prescribe the appropriate course of drug treatment. 3. New York State should ensure that drug treatment services for pregnant women are readily available on a voluntary, nonpunitive basis and should foster drug treatment in the context of promoting the health of the woman, her developing fetus, and the future child. 4. Medical and public health professionals should collaborate with criminal justice officials to improve health care in correctional facilities and to promote drug treatment in order to foster rehabilitation and to prevent recidivism. We support the availability of addiction services in all correctional settings for all substance users who seek treatment. 5. New York State should require health care insurers and managed-care entities, whether publicly supported or commercially sponsored, to provide coverage for drug treatment services. 6. We encourage the development of well-designed, adequately funded studies of the effectiveness of all treatment approaches and of new treatment methods, with a special focus on fostering research on effective pharmacological treatment agents for cocaine dependency. To promote such research, Congress should increase appropriations for substance abuse research at the National Institutes of Health (NIH), increasing the National Institute on Drug Abuse (NIDA) budget for treatment and medications development and for health services research. Z We will help create continuing medical education and specialized training programs for generalist physicians to increase knowledge of substance abuse identification and treatment. 8. We support efforts to amend federal, state, and local statutes and regulations to integrate methadone maintenance treatment into generalist care. We will promote the development and evaluation of innovative models of substance abuse treatment that integrate drug treatment services, including methadone maintenance, into generalist care. These approaches should be utilized for appropriate patients and be supported by specialty consultation. 9. We encourage the development of undergraduate medical education, residency training, and continuing medical education curricula that incorporate the knowledge, skills, and attitudes needed for effective addiction care. 10. Legal barriers to obtaining sterile needles and syringes should be removed. We support the enactment of the New York State legislative proposal to permit the sale by pharmacies of hypodermic needles and syringes without a prescription and to deregulate the distribution and possession of sterile needles and syringes as a costeffective approach to prevent HIV transmission. 11. We support increasing the availability of needle exchange programs to all those who seek such services; these programs should incorporate into their outreach services education on the proper disposal of needles. The New York State legislature should target and substantially increase appropriations for state-sponsored needle exchange programs to expand capacity at the state's 11 existing programs, develop new programs, and increase the availability of supplies necessary to implement needle exchange. In addition, we advocate rescinding the present ban on utilizing federal funds for needle exchange programs and research. January 29, 1997 This report of the New York Academy of Medicine seeks to promote a medical and public health framework for addressing substance use as a critical issue for urban health. Addressing substance use within a medical and public health perspective requires a renewed commitment to increase access to addiction treatment for all substance users seeking care and to reduce the individual and community harms associated with drug use, most importantly the transmission of human immunodeficiency virus (HIV).
PREAMBLE
Substance abuse and addiction treatments are fundamental concerns for the medical and public health communities. The New York Academy of Medicine, a leader in health policy, education, and promotion since 1847, has a longstanding commitment to contributing to rational discourse on treating substance abuse and in addressing its implications for the quality of urban life and commuo nity health. We believe that the fields of medicine and public health must seize the opportunity to address substance abuse as a priority issue for urban health. Drug addiction never has and never can be solved by policemen. It is first and last a medical problem, and if there is a solution it will be discovered not by policemen but by scientifically and competently trained medical experts)
Although drug abuse raises critical social, legal, and economic concerns that must be addressed if society is to address its root causes, addiction is an illness, and its treatment is a medical and public health matter. Its origins may be attributed to multigenerational poverty, governmental neglect, poor education, limited employment prospects, family dysfunction, and lack of hope. Drug abuse has been a scourge in our communities, especially in urban centers, and has resulted in family and community disintegration; transmission of HIV, hepatitis B and C, and other blood-borne diseases; the commission of violent crimes;
incarceration for drug-related offenses; lost productivity for significant proportions of our population; and, most significantly, lost and broken lives. The economic consequences to society are staggering--drug-related offenses consume massive legal and public safety resources in time and effort related to community law enforcement, criminal prosecutions, incarceration, and drug interdiction.
While we focus in this report on the medical and public health implications of substance use, the social, legal, and economic consequences also require attention.
The concept of treating addiction as a medical and public health issue is not new to the Academy of Medicine. As early as 1939, the Academy Committee on Public Health recommended the establishment of a privately endowed institution for the treatment of narcotics and alcohol addicts and for research into the causes of both addictions; this was envisioned as an experimental institution with facilities for vocational training and employment services. 2 In 1955, the Academy Committee on Public Health issued a six-point plan that included these recommendations:
1. The addict should be considered a sick person; it is unjust to consider him a criminal only because he uses drugs.
2. All existing addicts should be in medical treatment, with vigorous efforts toward their rehabilitation. 3
More recently, the Academy sponsored two major conferences related to drug use; one described the issues concerning drug testing in the workplace (1988), 4 and one focused on research and treatment for pregnant drug users (1990). 5 In 1991, the Academy issued policy statements addressing the links between sub-stance abuse and the HIV/AIDS (acquired immunodeficiency syndrome) epidemic; these statements called on drug treatment programs to provide HIV education and risk reduction, testing, and treatment6; the statements also called on the New York State legislature to amend the Public Health Law to permit over-the-counter sales by pharmacies and possession of hypodermic needles and syringes. 7 Finally, to promote discussion of innovative medical and public health approaches to drug treatment and harm reduction, the Academy conducted a conference in March 1995, bringing together and publishing the papers of leading international policymakers and researchers on addiction. 8
In New York City, injection drug use is the most common mode of HIV transmission, accounting for approximately 48% of all reported adult AIDS cases (as of March 31, 1997 ).* The primary focus of this report and its recommendations is heroin use, due largely to the desire to make an impact initially on one area of urgent, immediate concern: reducing the transmission of HIV among intravenous heroin users and to their sex partners and children. Medical care should prevent illness wherever possible, reach out to populations at greatest risk, provide the necessary care and services when individuals present themselves for treatment, and diminish the potential illness-related harms to individuals, families, and communities.
Second, addiction is a complex, chronic, relapsing illness for which various inpatient, residential, and outpatient treatments are used, depending on the substances involved, the intensity and duration of the addiction, the characteristics and tolerances of the patient, and the circumstances involved. The complexity of addiction treatment requires that generalists in medical care be knowledgeable and capable in the areas of diagnosis and management. Specialist consultation and care, as well as specific programs dedicated to the acute and chronic care of drug users, are also important components of care. In addition, optimal treatment *New York City Department of Health, Office of AIDS Surveillance, AIDS New York City, April 1997. Data include transmission categories "intravenous drug user" (45%), as well as "intravenous drug user and men who have sex with men" (3%).
requires the coordinated participation of appropriately qualified counselors, social workers, and other professionals.
Third, steps must be taken to reduce the health-related harms associated with injecting drug use, including the transmission of HIV, hepatitis B and C, and other blood-borne pathogens. Harm reduction incorporates many modalities, such as HIV prevention education, including condom use and safer sex counseling and education; referrals for drug treatment and other health care and social services; interim methadone maintenance; and syringe and needle availability and exchange programs. Each of these interventions represents important medical and public health strategies that may decrease some of the secondary medical consequences of injection drug use. OASAS further estimates that there are 600,000 regular users of illegal noninjecting drugs in New York State who need some type of treatment; the majority of these use cocaine or crack cocaine alone or in addition to heroin.
HEROIN TREATMENT: ~EVIEW OF THE: I~VIDENCE
There is a diverse range of modalities to treat heroin addiction; these incorporate initial detoxification, in conjunction with chemotherapy or residential, drug-free approaches. In New York City, the most common modality is chemotherapeutic maintenance with opiate substitutes--methadone or levo-alpha-acetyl-methadol (LAAM), a long-acting form of methadone (recently approved by OASAS for use in New York State)--that have been used to combat the symptoms of heroin withdrawal, stabilize the patient through maintenance doses, and facilitate engagement in a comprehensive program of rehabilitation. 15 ' 16 The effectiveness of methadone maintenance treatment in reducing or eliminating drug abuse has been documented. In one of the most comprehensive evaluations of the effectiveness of methadone maintenance treatment, sponsored by the National Institute on Drug Abuse (NIDA), Ball and Ross selected six methadone maintenance programs in New York City, Philadelphia, and Baltimore for intensive, on-site study during the mid-1980s; the studies included interviews with over 600 patients.
It was found that a reduction in drug abuse commonly occurs after admission and continues for as long as patients remain in outpatient treatment. When patients leave methadone maintenance programs, however, relapse to prior drug abuse patterns is the predominant outcome. 17(p 239) Adherence to therapy is also high. Attendance at the clinics was "surprisingly high," with daily attendance rates ranging from 92% to almost 100%. Heroin and other opiate use, as documented by patient interviews, declined markedly after admission. After 6 months in treatment, 77% of the patients had ceased heroin use; 92% had ceased using heroin after 4.5 years of treatment. Further, 71% of all patients studied ceased intravenous drug use after several years of treatment, although there was a wide range of individual program factors that played a role in successful cessation, with 90% of the patients at one site and only 43% of patients at another site no longer injecting drugs.
This study highlights the necessity of long-term methadone maintenance treat- Long-term rehabilitation is a primary goal of treatment; to this end, federal regulations require that programs offer a comprehensive range of services, ideally including substance abuse counseling, psychotherapy and psychiatric care; support groups; vocational rehabilitation; HIV counseling and testing and hepatitis and tuberculosis screening; and primary care. 2~ These services are intended to address significant patient concerns--such as mental health problems, chronic medical disorders, family dysfunction, unemployment, educational deficits, and legal difficulties--that may or may not be associated with drug use, but are not amenable to resolution through the use of methadone alone. Unfortunately, as the IOM report has noted, current practice at most programs consists of "at best, an evaluation of a newly admitted patient's medical and psychosocial treatment problems, followed by assignment to a paraprofessional 'counselor' who often has a 50-patient caseload "91p197) Rarely are services provided by staff with advanced professional training, even for those patients with serious medical, social, and psychiatric problems.
Some clinicians have argued that comprehensive multidisciplinary services are not a necessary adjunct to methadone treatment for many heroin users. If fewer services could be provided to some patients, the same resources potentially could serve a greater number of users. One model, developed by Yancovitz and his colleagues at New York's Beth Israel Medical Center, offers an interim approach to methadone treatment: dispensing methadone, but providing very limited services to heroin users on waiting lists for more-comprehensive care} 1
Interim services are not designed to replace comprehensive methadone treatment, but to provide care to users who would otherwise be on waiting lists and therefore be receiving no services at all.
In a study comparing interim patients with waiting list patients in a notreatment control group, the research team found that the interim group had reduced heroin use significantly (although no significant change was observed in cocaine use) and was more likely to participate in treatment at a 16-month follow-up. Although federal law was amended in 1992 and subsequent regulations now permit the provision of interim services, this approach has yet to be utilized widely, largely due to provider fears that its implementation would divert funding from comprehensive services and might lead legislators to reduce their per-slot budget allocations for maintenance patients. Methadone providers have a disincentive to wean patients from methadone dependence and into detoxification programs since the state funds the providers. Under the current law, the state is replacing one addiction with another at its own expense. behavior, development of employable skills, self-reliance, and personal honesty, 9 [which requires] a total 24-hour community impact. "2~ Therapeutic communities emphasize a self-help approach--utilizing program graduates as peer counselors, administrators, and role models. These programs provide long-term, highly structured, and intensive communal experiences, with a focus on highly confrontational group counseling sessions. Duration of treatment in therapeutic communities varies: although the traditional approach requires at least 15 months in residence, many programs offer shorter, more-flexible plans of with residency requirements of 3 to 6 months or 6 to 9 months. 26 For patients who desire to remain in the community, drug~free programs, which focus on professional counseling, are available on an outpatient basis.
These efforts range from "adaptive," drop-in crisis centers to highly structured, "change-oriented" programs that have as their goal the complete resocialization of patients to enable them to live drug free. 26(pp64~) Most participants of outpatient drug-free programs have not been regular heroin users.
Hubbard and his colleagues have contrasted the effectiveness of methadone maintenance, residential drug-free, and outpatient drug-free modalities. For those who stayed in treatment for at least 3 months, 64% of those in methadone maintenance, 31% of those in residential programs, and 9% of those in outpatient drug-free treatment were regular users of heroin (defined as using the drug weekly or daily) during the year before they entered treatment. Three to five years after leaving treatment, rates of regular heroin use declined to 18% for methadone, 12% for residential, and 5% for outpatient drug-free patients. Reductions in regular heroin use were most dramatic for those in methadone and residential treatment; length of time spent in treatment was the strongest predictor of treatment success, with at least 6 to 12 months in treatment necessary to produce positive outcomes. Moreover, about 25% of all clients were regular cocaine users (defined as using the drug once a week or more often) during the year before entering treatment, and about 60% had used the drug. Three to five years after leaving treatment, the percentage of regular cocaine users dropped to 6% to 16% across the three modalities 9 26(pp9~125) (1) Comprehensive methadone treatment, when combined with appropriate prenatal care, can reduce the incidence of obstetrical and fetal complications, in utero growth retardation, and neonatal morbidity and mortality. (2) There is no reported evidence of any significant toxic effects of methadone in the woman, fetus, or child, although such evidence has been sought. *The South Carolina Supreme Court ruled 3 to 2 that women who use illegal drugs during pregnancy can be prosecuted for child abuse, the first time a state Supreme Court upheld such criminal charges; top courts in Florida, Kentucky, Nevada, and Ohio have reached opposite conclusionsY Also see Ref. 28 , which discusses that the South Carolina Supreme Court upheld the criminal prosecution of a pregnant woman whose baby was born with systemic traces of cocaine; the court found that a viable fetus is a "person" covered by the state's child abuse laws. As discussed in Ref. 29 , the Florida Supreme Court ruled that a pregnant teenager who shot herself in the stomach after failing to obtain an abortion cannot be prosecuted for harming her fetus; also see Ref. 30 . Reference 31 discusses an alcohol-abusing woman who, while intoxicated, gave birth to a child with signs of fetal alcohol syndrome; she was charged with attempted murder. This is the first reported instance of a woman being prosecuted for murder when the fetus had not died.
Obstacles and barriers to methadone pharmacotherapy for pregnant women with opiate addiction.., must be removed. Pregnant opiate-addicted women need immediate access to methadone treatment services. ... necessary to obtain state and federally approved separate registration, it is rare for office-based physicians to detoxify an occasional opiate-dependent patient or provide maintenance treatment while they are simultaneously treating some concurrent psychiatric or other medical illness. 32
The legal segregation of drug treatment from primary care is promoted further by academic medicine: in the view of some, medical education at all levels has not provided generalist physicians with the knowledge, skills, or attitudes required to prescribe methadone effectively to treat heroin addiction. 33 In addition, residency training in general has not promoted such instruction. As a result, many primary care physicians "lack both the training and the desire to diagnose addictions. ,34
Allowing generalists (here referring to physicians specializing in internal medicine, family medicine, obstetrics/gynecology, or adolescent medicine, in addition to other physicians not subspecializing in substance abuse care) to prescribe methadone maintenance for heroin addicts who have been stabilized on treatment and for whom ancillary services can be provided elsewhere would create additional slots for patients who require more-comprehensive treatment and would increase access to drug treatment overall. Moreover, many patients might regard office-based treatment as significantly less stigmatizing than clinic services and therefore respond with greater compliance and decreased risk of relapse. The effectiveness of this approach has been demonstrated in studies of medical practices in western Europe, Hong Kong, and AustraliaY '36 Novick and colleagues have developed an innovative treatment model, referred to as medical maintenance, that permits primary care physicians to maintain socially rehabilitated former heroin addicts on methadone outside licensed clinics. 18(pp127-130) Although the patient cohort in this study was selected carefully--all patients had completed five years or more in conventional methadone treat-ment successfully; were employed; had verifiable financial support; and had no criminal involvement, use of illegal drugs, or excessive alcohol use within three or more years--the study demonstrated that former heroin users could be treated effectively in generalist physicians' offices; the patients had relatively high retention rates (the mean duration of treatment in medical maintenance was five years) and low incidence of substance abuse and lost medication. Based on this decadelong study, these researchers conclude that methadone maintenance should be made available through generalist physicians to many more patients and, with a short training program, could be provided by many physicians with or without prior experience in substance abuse treatment. Unlike methadone for the treatment of heroin addiction, there exists no effective pharmacologic substitute to treat cocaine addiction; most cocaine users are treated with psychosocial treatments within an abstinence approach. Patients with more-severe dependence, or those failing to respond to psychosocial treatment, may be treated additionally with dopaminergic medications, although the efficacy of these treatments has not been established, and adverse side effects are a concern, ls(pp36-38) Increasing support for research at NIDA for the development of innovative pharmacological and behavioral treatments to treat cocaine addiction should be a priority.
Although methadone is used as a pharmacologic substitute to treat heroin addiction, the NIDA-sponsored evaluation of methadone maintenance treatment found that cocaine abuse, as well as abuse of other nonopiate drugs, declined during methadone treatment. In this study, the sample of over 600 methadone maintenance patients had abused heroin regularly for an average of 11.2 years prior to treatment; of this group, 47% regularly abused cocaine for an average of 5.8 years. The length of time in treatment was found to correlate with decline in cocaine use: after 6 months in treatment, the prevalence of cocaine use declined to 28%. Moreover, after 4.5 years in treatment or longer, the prevalence rate for cocaine abuse declined to 17%. 17 These findings suggest that long-term methadone maintenance treatment may play an important role in reducing cocaine abuse associated with heroin addiction. Regardless of the funding streams used to finance treatment for heroin addiction or the modality used, treatment is cost effective to society whether measured by the prevention of HIV and family and community disintegration, the commission of violent crimes, incarceration for drug-related offenses, or lost productivity.
In its 1995 report, the IOM recommends that three objectives should guide drug policy and financing: reducing the severity of addiction to allow the addict to "maintain an acceptable level of medical and social functioning'a~ reducing crime and enhancing public safety; and safeguarding public health with the goal of reducing the transmission of HIV, hepatitis, and tuberculosis, a~ 2~ Further, While methadone maintenance can be seen as a service to or even a privilege for the affected individual because it reduces his/her withdrawal symptoms and cravings for opiates, to the extent that it is effective in reducing the social harm caused by these associated problems, methadone maintenance treatment may be seen as a public health benefit to society, similar to education and vaccination programs. 9(p196) Similarly, in its analysis of the costs related to substance abuse in New York City, the National Center on Addiction and Substance Abuse at Columbia University advised:
The public health benefits from reducing abuse and addiction would ripple through every facet of the city. It could mean fewer deaths of babies and teenagers, fewer crimes, fewer prison cells, fewer battered children and spouses, fewer drunk drivers, better conditions in existing housing stock, cleaner, safer parks, and an improved public education system. 41 Furthermore, methadone maintenance treatment has been found to be effective to society in terms of reducing crime. In the NIDA-sponsored evaluation of methadone maintenance programs, researchers found a significant reduction in crime after addicts entered methadone treatment. For those in treatment for six months or longer, there was a 79% decrease in the number of offenses committed from the number committed during their last addiction period--a decline from over 242,000 offenses to about 50,000 offenses. These declines in criminal activity were correlated with length of stay in treatment: although 37% of patients reported criminal behavior on admission to treatment, such activity decreased involvement of 22% of patients after one year in treatment and to 11% after six years of treatment. This reduction in crime was reported among patients at each of the programs studied, mp241)
In its evaluation of drug and alcohol treatment programs (known as the CALDATA study), the California Department of Alcohol and Drug Programs quantified the costs of reduced crime and found that drug treatment was cost effective to "taxpaying citizens. "43 Although the costs of treating approximately 150,000 patients in 1992 was $209 million, the benefits to taxpayers during treatment and the following year were worth about $1.5 billion in savings, mostly due to reductions in crime--by two-thirds from before to after treatment. "Each day of treatment paid for itself,.., primarily through an avoidance of crime."43(Piv)
One-third reductions in hospitalizations from before to after treatment were also reported, with corresponding significant improvements in other health indicators.
Although the cost-benefit ratio was highest for patients discharged from methadone treatment, the ratio for participants in residential programs was "still clearly economically favorable. "43(pv}
If it is inevitable that some people, in spite of elaborate societal constraints, will use illegal drugs and misuse legal ones, can medical intervention lessen the consequences of drug use? The concept of harm reduction, as used in this context, is that public health policies and programs should not be based on the ideal of a "drug-free society" or a society in which all persons always use drugs safely. 44
Rather, public policy must attempt to lessen the health and other societal consequences of drug use, particularly the transmission of HIV. The incidence of HIV infection derived from drug use is increasing steadily, especially in our cities, and adds immensely to the costs imposed by substance abuse. The New York
State AIDS Advisory Council has focused attention on:
the urgency of reducing HIV infection rates among substance users who are not ready for drug treatment, who relapse after treatment, whose multi-drug use is not comprehensively addressed by treatment programs, or for whom there is no available drug treatment program. Harm reduction services are designed to help injecting drug users along an individually paced developmental path toward greater and greater risk reduction. 42(pp34}
As in methadone treatment, in which many patients progress along a trajectory to become gradually less dependent on substances, harm-reduction services advance patients along a series of steps that gradually decrease the negative consequences of their drug use and can act as a bridge to treatment services.
Efforts to reduce HIV transmission among substance users incorporate many modalities, such as HIV prevention education, including condom use and safer sex counseling and education; referrals for drug treatment and other health care
and social services; interim methadone maintenance; bleach kits; and needle exchange and availability programs to reduce infection from shared needles. Community-based not-for-profit organizations and government entities engaged in clean hypodermic syringe and needle exchange programs designed to reduce the transmission of human immunodeficiency virus may obtain, possess and furnish hypodermic needles and syringes, without prescription, when authorized by the commissioner .... The authorization will be granted only in accordance with a plan.., approved by the commissioner Overall these studies indicate that needle-exchange programs can have an impact on bringing difficult to reach populations into systems of care that offer drug dependency services, mental health, medical and support services. These studies also indicate that needle exchange programs can be an effective component of a comprehensive strategy to prevent HIV and other blood borne infectious diseases in communities that choose to include them. 49
In spite of these official positions, the ban on federal support for needle-exchange Experience from Connecticut demonstrates that allowing pharmacies to sell needles and syringes offers a strategy for reducing the spread of HIV among drug users at no cost to the state. In 1992, the Connecticut legislature deregulated the purchase and possession of needles, allowing pharmacies to sell and individuals to possess up to 10 needles without a prescription. A 1995 study of the impact of this legal shift found that 9 Syringe sharing decreased after enactment of the new law (52% before vs. 31% after). 9 Fewer drug users reported purchasing syringes on the street after the new law (74% before vs. 28% after).
9 More drug users reported purchasing syringes from a pharmacy after the new laws (19% before vs. 78% after).
9 Over two-thirds (91 of 134) of active drug users interviewed 8 to 11 months after the law's enactment were aware of the legal change. 61
The authors, public health officers from the Centers for Disease Control and evidence that this practice encourages the use of illegal drugs, then the social benefits and health care goals might well be viewed as outweighing the possibility that needle exchange and needle availability programs may be perceived as condoning drug use. The obligation of the medical profession to treat these patients, decrease their burden of illness, and address the consequences of their addiction to third parties--most significantly, the transmission of HIV--is the critical concern. Current antidrug sentiment ought not preclude careful efforts to reduce the medical consequences of substance use. 64 
RECOMMENDATIONS
Addiction is an illness and its treatment is primarily a medical and public health matter. Because addiction treatment represents a cost-effective means of reducing HIV transmission, community violence, and family disintegration, the New York Academy of Medicine recommends the following:
1. We support significantly increased funding for addiction treatment, including methadone treatment, residential drug-free programs, and other modalities.
2. The level and duration of drug treatment should be a medical determination. We oppose legislative or regulatory proposals to prescribe the appropriate course of drug treatment.
3. New York State should ensure that drug treatment services for pregnant women are readily available on a voluntary, nonpunitive basis and should foster drug treatment in the context of promoting the health of the woman, her developing fetus, and the future child.
4. Medical and public health professionals should collaborate with criminal justice officials to improve health care in correctional facilities and to promote drug treatment in order to foster rehabilitation and to prevent recidivism. We support the availability of addiction services in all correctional settings for all substance users who seek treatment.
5. New York State should require health care insurers and managed-care entities, whether publicly supported or commercially sponsored, to provide coverage for drug treatment services.
6. We encourage the development of well-designed, adequately funded studies of the effectiveness of all treatment approaches and of new treatment methods, with a special focus on fostering research on effective pharmacological treatment agents for cocaine dependency. To promote such research, Congress should increase appropriations for substance abuse research at the National Institutes of Health (NIH), increasing the National Institute on Drug Abuse (NIDA) budget for treatment and medications development and for health services research.
7. We will help create continuing medical education and specialized training programs for generalist physicians to increase knowledge of substance abuse identification and treatment.
8. We support efforts to amend federal, state, and local statutes and regulations to integrate methadone maintenance treatment into generalist care.
We will promote the development and evaluation of innovative models of substance abuse treatment that integrate drug treatment services, including methadone maintenance, into generalist care. These approaches should be utilized for appropriate patients and be supported by specialty consultation.
9. We encourage the development of undergraduate medical education, residency training, and continuing medical education curricula that incorporate the knowledge, skills, and attitudes needed for effective addiction care. 
